A radioimmunoassay system has been developed for the measurement of two major metabolites of 9,3"-diacetylmidecamycin, immunoassay for Mb-6 was performed by using anti-Mb-6 serum and a [1251I]tyramined Mb-6 derivative as a radiolabeled antigen. The labeled antigen was prepared by the chloramine T method. The antiserum was obtained from a rabbit immunized with Mb-6 conjugated to bovine serum albumin. The obtained antiserum was cross-reactive with two other metabolites of 9,3"-diacetylmidecamycin, Mb-2 and Mb-12, in addition to Mb-6. This Mb-6 radioimmunoassay system could detect Mb-6 concentrations as low as 100 pg/ml of serum. The coefficients of variation were 4.5% (intra-assay) and 5.1% (inter-assay). A radioimmunoassay for Mb-12, using anti-midecamycin serum and a [1251]tyramined-Mb-12 derivative, has also been developed. The antiserum was crossreactive only with Mb-12 among the 9,3"-diacetylmidecamycin metabolites. This Mb-12 radioimmunoassay system could detect Mb-12 concentrations as low as 2 ng/ml. The intra-and inter-assay variances were 5.9 and 5.8%, respectively. antimicrobial assay in vitro, is almost the same as that of MOM (5). The structures of MOM and its metabolites, as well as of MDM, are given in Fig. 1 .
9,3"-Diacetylmidecamycin (MOM) is a derivative of a macrolide antibiotic, midecamycin (MDM). These 1979 ). MOM has a higher potency and lower toxicity than other macrolides; its therapeutic effects are observed at doses half those of other macrolides. It has been reported that MOM administered orally to humans is rapidly metabolized to Mb-1 before it reaches the liver, and this product is then immediately metabolized through two metabolic pathways (1, 4) . The major metabolic pathway is from Mb-1 to Mb-9a via Mb-12 and Mb-6, and the minor one is from Mb-1 to Mb-9a or Mb-9b via Mb-2, Mb-3, and Mb-5. The major metabolites in blood or urine are Mb-6, Mb-12, and Mb-9a. Neither unchanged MOM nor Mb-1 is detectable in either blood or urine by chemical assays using thin-layer chromatography (1 antimicrobial assay in vitro, is almost the same as that of MOM (5) . The structures of MOM and its metabolites, as well as of MDM, are given in Fig. 1 .
To examine the relationship between the efficacy of MOM and the blood level of MOM metabolites, a sensitive assay system for MOM metabolites is required. Macrolide antibiotics have been measured by antimicrobial assay or chemical assay (1, (4) (5) (6) ; however, these methods are unsuitable for the routine assay for MOM metabolites because they are insensitive and time-consuming for the treatment of a large number of samples. In the present study, we aimed to establish a radioimmunoassay ( subcutaneously once a month for 3 months. The rabbits were bled 10 days after the last immunization. Antisera against Mb-6 and MDM which showed the highest titer were used in the present RIA system. )led to BSA by using succinic anhydride as a cross-RIA procedures. A diluent for reagents was 10 mM inking agent and were then used as antigens. sodium phosphate buffer containing 0.5% BSA, 25 mM Mb-6 (1.9 g) and succinic anhydride (380 mg) were EDTA, and 0.9%o NaCl, pH 7.4 (PBS-BSA). The lissolved in 5 ml of anhydrous pyridine and stirred reaction mixture contained the following reagents in a ivernight at room temperature. The reaction mixture plastic tube: 0.4 ml of PBS-BSA, 0.1 ml of standard or vas applied on a column of SiO2 (1.5 by 35 cm), and sample solution, 0.1 ml of 20-fold-diluted antiserum vfb-6 2'-hemisuccinate was eluted with chloroform-(anti-Mb-6 serum or anti-MDM serum), and 0.1 ml of nethanol (19:1, vol/vol) to yield 1.4 g. The obtained tracer ([125I]tyramine-suc-Mb-6 or [1251]tyramine-suciemisuccinate (150 mg) and BSA (500 mg) were dis-Mb-12, about 10,000 cpm). Tubes prepared in dupli-;olved in 8 ml of water. To this solution was added 3.0 cate were incubated overnight at 4°C. Bound and free of 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide antigens were separated by using dextran-coated charydrochloride in S ml of water. After stirring overnight coal as follows. To each tube, 1 ml of sodium phost 4°C, the reaction mixture was dialyzed against water phate buffer containing 1 mg of dextran T-70 and 10 mg or 2 days and was then lyophilized. The yield of the of charcoal (pH 7.4) was added. The tubes were *esulting conjugate (termed Mb-6-suc-BSA) was 565 incubated at 4°C for 30 min and then centrifuged at ng. 1,600 x g for 15 min at 4°C. The radioactivity of the MDM 2'-hemisuccinate was separated from a mix-supernatant fluid was determined in an Aloka Autoure of MDM (388 mg) and succinic anhydride (72 mg) gamma counter. n 2 ml of anhydrous pyridine by using column chroSpecific binding was expressed as the difference of natography on SiO2. The hemisuccinate (150 mg) and radioactivity between the presence and absence of 3SA (374 mg), dissolved in 6 ml of water, were antiserum. The specific binding was 3,000 to 4,000 :onjugated by the addition of 1-ethyl-3-(3-dimethyl-cpm in RIAs using anti-Mb-6 serum and anti-MDM uninopropyl)carbodiimide hydrochloride (3.07 g) in 4 serum. ml of water, followed by stirring at room temperature for 5 h. The reaction mixture was dialyzed against water at 4C for 2 days and then lyophilized. The yield of MDM-suc-BSA conjugate was 363 mg.
Preparation of tracer. Mb-6 2'-hemisuccinate (42 mg), tyramine hydrochloride (13 mg), and N-hydroxybenzotriazole (10 mg) were dissolved in 1 ml of dimethylfonnamide. To this solution was added 12 mg RESULTS Specificity. To test the specificity of anti-Mb-6 serum and anti-MDM serum for MOM metabolites such as Mb-2, Mb-3, Mb-5, Mb-6, Mb-9a, Mb-9b, and Mb-12, cross-reactivity studies were conducted (Fig. 2) . Cross-reactivity was expressed as the relative potency of each metabolite, compared to that of Mb-6, for 50%o displacement of labeled Mb-6. The percentages of cross-reactivity of anti-Mb-6 serum for Mb-2 and Mb-12 were 84 and 202%, respectively (Table 1) a As determined by the relative amounts needed for 50% displacement of radioactive antigen.
91.9%o. Similary, in RIA for Mb-12, the percentage of recovery at each concentration was 125.0, 106.1, and 96.0%, respectively, and the mean recovery was 109.0%o.
Reproducibility. The reproducibility in the
RIAs for Mb-6 and Mb-12 was estimated from the coefficient of variation (CV) in intra-assay and inter-assay systems. To determine inter-and intra-assay CVs, 10 replicates of metabolitecontaining sera were measured in the same assay at three different concentrations (Table 2) .
Serum Mb-6 and Mb-12 levels. The concentrations of Mb-6 equivalent and Mb-12 in the sera of patients orally administered 200 mg of MOM were measured by RIA. The typical patterns of serum levels of these metabolites are shown in Fig. 3 . The concentration of Mb-6 equivalent in the serum was about threefold that of Mb-12.
DISCUSSION
The major metabolites of MOM in humans are Mb-6, Mb-12, and Mb-9a in blood and Mb-6 and Mb-12 in urine (1) . In the present study, we attempted to develop an RIA system to assay Mb-6 and Mb-12 in biological fluids.
In the present RIA systems, anti-Mb-6 serum was cross-reactive with two other MOM metabolites, Mb-12 and Mb-2, whereas anti-MDM serum was cross-reactive only with Mb-12. Therefore, the RIA system using anti-MDM serum is effective for the determination of Mb-12 because MDM is not found in MOM metabolites (1) . Sufficient amounts of Mb-12 to immunize rabbits could not be obtained; however, the structure of MDM is similar to that of Mb-12 except for the 4" position (MDM, 4"-propionyl; Mb-12, 4"-acetyl), so MDM conjugated to BSA was used as the antigen to obtain the antiserum used in the RIA for Mb-12. It has been reported that the Mb-2 concentration in human blood or urine is slight (1) . Therefore, the Mb-6 equivalent concentration in biological fluids, obtained by the present RIA, was supposed to be the sum of Mb-6 and Mb-12. The reason why anti-Mb-6 serum exhibited higher affinity to Mb-12 than to Mb-6 is unclear.
The sensitivities of the present RIA system, expressed as the response equal to twice the standard deviation of a duplicate assay without unlabeled Mb-6 or Mb-12 were 0.1 ng/ml of serum in the RIA for Mb-6 and 2 ng/ml of serum in the RIA for Mb-12. These sensitivities are enough to determine concentrations of these MOM metabolites in the blood of a human administered the therapeutic dose of MOM. The sensitivities of both RIA systems were slightly lower in the determination of these metabolites in urine or buffer. However, high concentrations of these metabolites are ordinarily present in urine, so the lower sensitivity is not a practical problem.
Macrolide antibiotics have been measured by antimicrobial assay or chemical assay systems. Metabolites of these antibiotics cannot be measured separately by antimicrobial assay, but can be detected by chemical assay using thin-layer chromatography. However, the sensitivity of both chemical and antimicrobial assays is less than that of RIA. The RIA systems described in the present paper, therefore, appear to be suitable for the sensitive measurement of metabolites of MOM.
